Hispanic Broadcasting

Hispanic Broadcasting Newswire

Comprehensive Real-Time News Feed for Hispanic Broadcasting.

Results 1 - 20 of 195 in Hispanic Broadcasting

  1. Hospira, Inc. To Host Conference Call For Fourth-Quarter 2014 Results And 2015 ProjectionsRead the original story

    Wednesday | BioSpace

    A live webcast of the conference call and related material will be available on Hospira's website at www.hospirainvestor.com . Listeners should log on approximately 10 minutes in advance to ensure proper setup to receive the webcast.

    Comment?

  2. Hospira to Host Conference Call for Fourth-Quarter 2014 Results and 2015 ProjectionsRead the original story

    Thursday | Freshnews

    Hospira, Inc. , the world's leading provider of injectable drugs and infusion technologies, and a global leader in biosimilars, will host a conference call to discuss its fourth-quarter and full-year 2014 results and projections for 2015 on Thursday, Feb. 12, 2015 at 8 a.m. Central time. The company will release its fourth-quarter and full-year results earlier that morning, before the U.S. stock market open and the conference call.

    Comment?

  3. Hospira 'committed to quality' as total recall count hits 40 since 2012Read the original story w/Photo

    Tuesday Jan 27 | In-PharmaTechnologist.com

    A human hair found in a vial of Sodium Chloride Injection has led to the fortieth recall in three years for Hospira. The particulate matter was found by a customer in a single unit of Hospira's 0.9% Sodium Chloride Injection, and was confirmed by the company to be a human hair "sealed in the bag at the additive port area."

    Comment?

  4. 0.9 Percent Sodium Chloride Injection, USP, 250 mL by Hospira : Recall - Particulate MatterRead the original story w/Photo

    Thursday Jan 22 | Drugs.com

    ISSUE : Hospira, Inc. announced a voluntary nationwide recall of one lot of 0.9% Sodium Chloride Injection, USP, 250 mL to the user level due to one confirmed customer report of particulate in a single unit. Hospira has identified the particulate as a human hair, sealed in the bag at the additive port area.

    Comment?

  5. Hospira Receives U.S. FDA Approval of Proprietary Analgesic Dyloject (diclofenac sodium) InjectionRead the original story w/Photo

    Dec 30, 2014 | Drugs.com

    Hospira, Inc. , the world's leading provider of injectable drugs and infusion technologies, and a global leader in biosimilars, has received approval from the U.S. Food and Drug Administration for Dyloject Injection, a proprietary nonsteroidal anti-inflammatory drug analgesic. Dyloject is indicated for use in adults for the management of mild to moderate pain and for the management of moderate to severe pain alone or in combination with opioid analgesics.

    Comment?

  6. Mitoxantrone by Hospira: Recall - Confirmed Subpotency and Out-Of-SpecificationRead the original story w/Photo

    Dec 22, 2014 | Drugs.com

    ISSUE : Hospira, Inc. announced today it has initiated a worldwide voluntary recall to the user level of 10 lots of MitoXANTRONE , due to confirmed subpotency and elevated impurity levels. Risk factors associated with these types of out of specifications may include the potential for decreased potency which can lead to decreased effectiveness, additional dosing and the potential for cumulative impurity toxicity requiring medical intervention.

    Comment?

  7. Hispanic Radio Conference...Read the original story w/Photo

    Monday Jan 26 | Radio Ink

    ... agency business from Dallas, Austin, Houston, and San Antonio. He left Univision Television for Hispanic Broadcasting Corp. in 1999, building the HBC Radio Network from 37 stations to 72, with programs including Julie Stav, the Latin GRAMMY Awards, ...

    Comment?

  8. Hospira Issues a Voluntary Nationwide Recall of One Lot of 0.9%...Read the original story

    Friday Jan 23 | US Food and Drug Administration

    January 20, 2015 - LAKE FOREST, Ill., - Hospira, Inc. , announced today it will initiate a voluntary nationwide recall of one lot of 0.9% Sodium Chloride Injection, USP, 250 mL to the user level due to one confirmed customer report of particulate in a single unit. Hospira has identified the particulate as a human hair, sealed in the bag at the additive port area.

    Comment?

  9. Feeling Good With This Med CompanyRead the original story

    Tuesday Jan 20 | GuruFocus.com

    In this article, let's take a look at Hospira Inc. , a $10.7 billion market cap company, which provides a variety of hospital products, including injectable generic drugs, pumps and syringes. The company was created on May 2004, as a spinoff from Abbott Laboratories .

    Comment?

  10. Hospira infusion system OKa d by FDARead the original story

    Tuesday Jan 20 | Chicago Sun-Times

    Hospira Inc. plans to have a new infusion system available in the United States within weeks after it received approval from the U.S. Food and Drug Administration. The Lake Forest maker of injectable drugs and infusion systems said Tuesday its Plum 360 system with Hospira MedNet had been cleared by the FDA.

    Comment?

  11. Hospira Receives FDA Clearance for Plum 360(TM) Infusion SystemRead the original story

    Tuesday Jan 20 | Freshnews

    Hospira, Inc. , the world's leading provider of injectable drugs and infusion technologies, today announced that the company has received 510 regulatory clearance from the U.S. Food and Drug Administration for the Plum 360 infusion system with Hospira MedNet safety software. The newest in Hospira's portfolio of infusion devices, the Plum 360 system builds on the unique air management and secondary delivery features of Plum A+ , while expanding its drug library and wireless capability to enable streamlined electronic medical record integration.

    Comment?

  12. Hospira Receives FDA Clearance for Plum 360 Infusion SystemRead the original story

    Tuesday Jan 20 | Benzinga

    Hospira, Inc. , the world's leading provider of injectable drugs and infusion technologies, today announced that the company has received 510 regulatory clearance from the U.S. Food and Drug Administration for the Plum 360a infusion system with Hospira MedNeta safety software. The newest in Hospira's portfolio of infusion devices, the Plum 360 system builds on the unique air management and secondary delivery features of Plum A+a , while expanding its drug library and wireless capability to enable streamlined electronic medical record integration.

    Comment?

  13. Three Market Leading Healthcare PicksRead the original story w/Photo

    Tuesday Jan 20 | Forbes.com

    I began analyzing the financial markets in 1982 when I became the research director for a financial advisory firm and provided regular market analysis on stocks, commodities, currencies and mutual funds. I am a technical analyst.

    Comment?

  14. Drug manufacturer Hospira closing Clayton plant, cutting 250 jobsRead the original story w/Photo

    Wednesday Jan 14 | Local Tech Wire

    Hospira, a manufacturer of injectable and other drug products as well as medical devices, is closing its plant in Clayton which employs some 250 people. Hospira says the facility will close in the second half of this year.

    Comment?

  15. Hospira, Inc. to Shutter Plant, 250 Workers AffectedRead the original story

    Tuesday Jan 13 | BioSpace

    A company that has been part of a cluster of biomanufacturers in Johnston County for more than a decade is closing its Clayton plant. Hospira, which makes injectable drugs and other medical products, said on Tuesday that it will stop producing and shipping medicines from its facility on U.S. 70 Business in June.

    Comment?

  16. Hospira to close North Carolina plantRead the original story

    Tuesday Jan 13 | Chicago Sun-Times

    The Lake Forest maker of injectable drugs and medical devices said products made at the plant in Clayton, North Carolina, will be transferred to other Hospira facilities or contracted out to other companies. Hospira will take pre-tax charges totaling $45 million for the closure, including a $22 million non-cash charge in the fourth quarter of 2014.

    Comment?

  17. Technical Coverage on Pharma Stocks - Hospira, Auxilium Pharma,...Read the original story

    Tuesday Jan 13 | Sys-Con Media

    Investor-Edge has initiated coverage on the following equities: Hospira Inc. , Auxilium Pharmaceuticals Inc. , The Medicines Company , SciClone Pharmaceuticals Inc. , and Nektar Therapeutics . Free research on these five companies can be accessed at: http://investor-edge.com/register , the NASDAQ Composite ended at 4,664.71, down 0.84%, the Dow Jones Industrial Average declined 0.54%, to finish the day at 17,640.84, and the S&P 500 closed at 2,028.26, down 0.81%.

    Comment?

  18. Hospira, Inc. Announces Significant Progess On Global Device StrategyRead the original story

    Wednesday Jan 7 | BioSpace

    The global device strategy, initiated in 2013, establishes a streamlined and modernized device portfolio to address customer needs and to position the company for future innovation and growth, all while supporting continued advancement of device remediation, including quality improvement efforts. Progress announced today includes the lifting of the import alert on the company's portfolio of infusion devices by the U.S. Food and Drug Administration , the introduction of next-generation pumps and details on future technology development.

    Comment?

  19. FDA Approves Hospira's Dyloject InjectionRead the original story w/Photo

    Friday Jan 2 | Pharmaceutical Processing

    Hospira has received approval from the FDA for Dyloject Injection, a proprietary nonsteroidal anti-inflammatory drug analgesic. Dyloject is indicated for use in adults for the management of mild to moderate pain and for the management of moderate to severe pain alone or in combination with opioid analgesics.

    Comment?

  20. FDA approves Hospira's Dyloject (diclofenac sodium) Injection for pain managementRead the original story w/Photo

    Dec 30, 2014 | Medical News

    Hospira, Inc. , the world's leading provider of injectable drugs and infusion technologies, and a global leader in biosimilars, has received approval from the U.S. Food and Drug Administration for Dyloject Injection, a proprietary nonsteroidal anti-inflammatory drug analgesic. Dyloject is indicated for use in adults for the management of mild to moderate pain and for the management of moderate to severe pain alone or in combination with opioid analgesics.

    Comment?